Table 2 Patient characteristics, demographic data, and comorbidities

Sex (female) (n, %)

123 (66.5)

66 (80.5)

p = 0.022

67 (76.1)

p = 0.107

Age (median, IQR)

45.0 (38.0–50.0)

45.5 (37.0–53.3)

p = 0.105

44 (39.0–51.0)

p = 0.519

Age at first event (median, IQR)

37.5 (29.0–43.0)

35 (30.0–40.4)

p = 0.609

35 (27.0–43.0)

p = 0.241

 Thrombosis only (n, %)

166 (89.7)

61 (74.4)

p = 0.002

59 (67.0)

p < 0.001

 Obstetric morbidity only (n, %)

18 (9.7)

16 (19.5)

p = 0.022

24 (27.3)

p < 0.001

 Both (n, %)

1 (0.5)

5 (6.1)

p = 0.025

5 (5.7)

p = 0.029

 Anti-β2GPI

-

-

-

45 (51.1)

-

 LA

-

-

-

35 (39.7)

-

 aCL

-

-

-

24 (27.3)

-

 Double positive

-

-

-

17 (19.3)

-

 Triple positive

-

-

-

1 (1.1)

-

Associated AID (n, %)

16 (8.6)

15 (18.3)

p = 0.026

11 (12.5)

p = 0.322

 SLE

2 (1.1)

6 (7.3)

p = 0.017

2 (2.3)

p = 0.454

 Plausible evolution to SLE

4 (2.2)

2/76 (2.6)

p = 0.828

4/86 (4.7)

p = 0.278

 Antinuclear antibodies

34/142 (23.9)

37/73 (50.7)

p < 0.001

29/76 (38.2)

p = 0.026

 Diabetes

9 (4.9(

3 (3.7)

p = 0.662

1 (1.1)

p = 0.160

 Smoker

66 (35.7)

27 (32.9)

p = 0.664

19 (21.6)

p = 0.02

 Arterial hypertension

23 (12.4)

17 (20.7)

p = 0.083

13 (14.8)

p = 0.594

 Obesity

39 (21.1)

15 (18.3)

p = 0.601

16 (18.2)

p = 0.577

 Dyslipidaemia

56 (30.3)

26 (31.7)

p = 0.814

26 (29.5)

p = 0.461

 Hyperuricemia

5 (2.7)

6 (7.3)

p = 0.091

3 (3.4)

p = 0.707

 Hereditary thrombophilia

24 (13.0)

6 (7.3)

p = 0.214

12 (13.6)

p = 0.768

 Oral contraceptive pill

76 (41.1)

19 (23.2)

p < 0.001

24 (27.3)

p = 0.002